Navigation Links
Mayo Clinic Proceedings Reviews Deep Brain Stimulation to Treat Psychiatric Diseases
Date:6/29/2009

ROCHESTER, Minn., June 29 /PRNewswire-USNewswire/ -- Pioneering therapeutic trials to investigate the effectiveness of deep brain stimulation (DBS) in hard-to-treat depression, obsessive-compulsive disorder (OCD) and Tourette's syndrome are underway at multiple medical centers around the world, according to a review in the June 2009 issue of Mayo Clinic Proceedings. "Deep brain stimulation has long been seen as valuable for controlling movement disorders," according to the review, written by Susannah Tye, Ph.D., Mark Frye, M.D., from the Mayo Clinic Department of Psychiatry and Psychology, and Kendall Lee, M.D., Ph.D., Mayo Clinic Department of Neurosurgery. "It now is being investigated for hard-to-treat psychiatric disorders," according to the authors.

"Early results indicate the effect on depression and obsessive compulsive disorder is beneficial, but the therapy needs further study," Dr. Lee says. The potential for this breakthrough treatment is enormous in reducing the toll of mental illness on patients, their families and society, according to the review.

Unlike electroshock therapy (ECT), which stimulates the entire brain, DBS stimulates specific parts of the brain. DBS is thought to be functionally equivalent to creating a lesion on the brain, but with the advantage of being adjustable and reversible.

"It is like implanting a pacemaker for the brain," says Dr. Lee. The patient is awake during deep brain stimulation surgery while a neurosurgeon implants the electrodes. Patients are able to give immediate feedback. Additionally, patients do not feel any pain during the implantation procedure since the brain is without pain receptors.

In the developed world, major depression is second only to cardiovascular disease in premature mortality and time lived with disability according to the review. In persons aged 15 to 44 years, depression is the most disabling medical illness in the United States. The prevalence of major depression, known to be a chronic and relapsing illness, is approximately 17 percent, affecting almost 1 in 5 persons.

Medications and psychiatric therapy can effectively treat many patients with major depression; however, up to 20 percent of these patients fail to respond to these non-surgical therapeutic interventions.

"DBS is not a miracle cure and should not be used to treat all depression," says Dr. Lee. "It should be reserved for those patients who have treatment-resistant depression and approved by a multi-disciplinary team." Ongoing advances in DBS technologies represent an important new field that could greatly advance the understanding of psychiatric neurobiology, according to the review.

A peer-review journal, Mayo Clinic Proceedings publishes original articles and reviews dealing with clinical and laboratory medicine, clinical research, basic science research and clinical epidemiology. Mayo Clinic Proceedings is published monthly by Mayo Foundation for Medical Education and Research as part of its commitment to the medical education of physicians. The journal has been published for more than 80 years and has a circulation of 130,000 nationally and internationally. Articles are available online at www.mayoclinicproceedings.com.

VIDEO ALERT: Additional audio and video resources, including excerpts from an interview with Dr. Kendall Lee describing the research, are available on the Mayo Clinic News Blog.

About Mayo Clinic

Mayo Clinic is the first and largest integrated, not-for-profit group practice in the world. Doctors from every medical specialty work together to care for patients, joined by common systems and a philosophy that "the needs of the patient come first." More than 3,300 physicians, scientists and researchers and 46,000 allied health staff work at Mayo Clinic, which has sites in Rochester, Minn., Jacksonville, Fla., and Scottsdale/Phoenix, Ariz. Collectively, the three locations treat more than half a million people each year. To obtain the latest news releases from Mayo Clinic, go to www.mayoclinic.org/news. MayoClinic.com (www.mayoclinic.com) is available as a resource for your health stories. For more on Mayo Clinic research, go to www.mayo.edu.


'/>"/>
SOURCE Mayo Clinic
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237
2. Infant Formula Company Teams With the University of Virginia Pediatrics Department to Conduct Clinical Studies
3. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
4. West Wireless Health Institute Teams with Corventis for its First Multicenter, Randomized Clinical Trial
5. Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies
6. DIA Annual Meeting Attendees Invited to Participate in Electronic Data Capture (EDC) Clinical Trial Survey
7. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
8. New Safety Regulations Drive Greater Need for Resources and Expertise at Every Stage of Clinical Development
9. ProFibrix Initiates Phase II Clinical Trial of its Lead Topical Hemostat Product Fibrocaps(TM)
10. Clinical and Histopathological Results Using Pollogens TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy
11. HEALTHPOINT-Sponsored Venous Leg Ulcer Clinical Trial Enrolls First Subject for Second Phase II Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2017)... 29, 2017  Cellect Biotechnology Ltd. (NASDAQ: ... enables the functional selection of stem cells, today provided ... first quarter ended March 31 st , 2017. ... in the first quarter of 2017," said Dr. Shai ... announced the treatment of the first blood cancer patient ...
(Date:5/23/2017)... 23, 2017  Leaf Healthcare, recognized for developing ... for pressure ulcer prevention, will unveil its comprehensive ... Critical Care Nurses, National Teaching Institute and Critical ... The Leaf Patient Monitoring System is the first ... environment.  The system seamlessly tracks patient movement throughout ...
(Date:5/18/2017)... , May 17, 2017  Bayer announced today that ... will be presented at the 53 rd Annual ... taking place June 2-6 in Chicago ... ASCO span prostate, colorectal, liver and thyroid cancers, as ... the Phase II CHRONOS-1 trial of copanlisib in patients ...
Breaking Medicine Technology:
(Date:6/20/2017)... ... ... With certifications and experience that puts them at the top of the field ... currently accepting new patients at their practice for these custom clear aligners. These qualified ... why they offer the latest in modern dental techniques to ensure that all their ...
(Date:6/20/2017)... ... June 20, 2017 , ... Many ... their regulatory principles, the research team developed expressRNA, a web platform encompassing computational ... This reveals at nucleotide resolution the ‘RNA maps’, which demonstrate that RBPs bind ...
(Date:6/20/2017)... ... June 20, 2017 , ... Total Security Integrated Systems, one ... the partner of choice by Amtrak to fulfill several projects in various Northeast ... long-distance intercity service in the contiguous United States. Security Executives at the company ...
(Date:6/20/2017)... ... June 20, 2017 , ... Uniworld Boutique River Cruise Collection ... latest all-inclusive boutique ship, S.S. Joie de Vivre . What really sets this ... France’s Seine River and designed small enough to dock directly in Paris. With The ...
(Date:6/20/2017)... ... June 20, 2017 , ... The law firm of Momkus McCluskey Roberts ... president of the DuPage County Bar Association’s Board of Directors. Cassioppi officially took on ... the Drake in Oak Brook. Momkus McCluskey Roberts LLC attorney Stacey A. McCullough was ...
Breaking Medicine News(10 mins):